Certified by Founder Lodge
DCVC Bio
United States - Palo Alto, California
INVESTOR
1 Disclosed Funding Rounds $50,000,000
7 Participating Investments
-
Operating Status
Active
-
Last Funding Type
Seed
-
Company Type
For Profit
- Website
- Contact
- Social Links
DCVC Bio is a VC fund investing in early-stage computational biology startups. Advances in genetic sequencing, artificial intelligence and automation are converging to transform existing life
| Company | Date | Round | Raised |
|---|---|---|---|
 Unlearn.AI |
April, 19 ,2022 | Series B | $50,000,000 |
 Ascend Gene & Cell Therapies |
May, 10 ,2023 | Series A | $132,500,000 |
 Solu Therapeutics |
August, 01 ,2023 | Seed | $31,000,000 |
 CH4Global |
August, 30 ,2023 | Series B | $29,000,000 |
 Radionetics Oncology |
January, 04 ,2024 | Series A | $52,500,000 |
 Elo Life Systems |
January, 25 ,2024 | Series A | $20,500,000 |
 Latus Bio |
May, 03 ,2024 | Series A | $54,000,000 |
Cherry Ventures
Blue Bear Capital
Slow Ventures
Climate Capital
Eniac Ventures
Transaera, Inc. | $10,500,000 | (Nov 5, 2024)
Algebrik AI | $4,000,000 | (Nov 5, 2024)
Insider. | $500,000,000 | (Nov 5, 2024)
Cintoo | $40,246,701 | (Nov 5, 2024)
Advex AI | $3,500,000 | (Nov 5, 2024)
